Switzerland-based Actelion, developer of two approved pulmonary arterial hypertension (PAH) drugs Opsumit (macitentan) and, more recently, Uptravi (selexipag), announced that it will present updates on company growth and future plans at investor conferences in the near future. Actelion is in the process of transforming is PAH portfolio and developing its R&D pipeline of…
Right ventricular dysfunction is intimately linked to pulmonary hypertension (PH). Since the dynamics of the two ventricles of the heart are connected through the shared tissue of the septum – the wall between the two ventricles – the team behind a new British study hypothesized that the left ventricle would also be affected in PH,…
Sildenafil (Revatio) — a phosphodiesterase type-5 inhibitor developed by Pfizer – is approved for the treatment of pulmonary arterial hypertension (PAH) in adults. Two large international clinical trials, the STARTS I and II trials, subsequently investigated the safety of sildenafil use in children. Based on their findings, however, the U.S. Food and Drug Administration (FDA) and the…
Get regular updates to your inbox.